📅 Thursday September 11th, 2025 | 📍 IMI Campus, Sandyford | 👥 Limited to 25 attendees
About the Masterclass
If you work in market access or reimbursement, this intensive one-day masterclass is an unmissable opportunity to deepen your expertise, engage with leading voices, and strengthen your professional network.
Delivered in an interactive, classroom-style format, the session will explore reimbursement processes, HTA strategies, and patient access frameworks — with a strong focus on real-world insights and practical application.
What You’ll Gain
-
Direct engagement with senior experts in an intimate 25-seat setting
-
Actionable strategies for navigating reimbursement and HTA landscapes
-
A deeper understanding of patient access frameworks and stakeholder expectations
-
Meaningful peer-to-peer networking opportunities
Key Topics
-
Reimbursement landscape overview & timelines
-
Evolution of reimbursement processes in Ireland & across Europe
-
NCPE insights on EU HTA rollout
-
Real-world perspectives from Ecker & Ecker GmbH
-
Industry perspectives on access challenges and trends
-
Patient engagement & advocacy strategies and best practices
Who Should Attend?
This masterclass is tailored for professionals in market access, reimbursement, and related roles, as well as those with a strong understanding of HTA processes who want to sharpen their expertise.
The event is open to both PMI members and non-members. Registration includes course materials, breakfast, and lunch.
——-
Meet the speakers:
Claire Barry, Head of Consulting – Salutem Insights
Claire is an accomplished pharmaceutical professional with over 20 years of experience focused on health economics and patient access. With a PhD in Neurophysiology from Trinity College Dublin and a Postgraduate Certificate in Health Economics from the University of York, she combines scientific depth with strategic leadership. Formerly Head of Patient Access at Bayer Pharmaceuticals and a member of the IPHA Market Access Advisory Forum, Claire has secured reimbursement for a broad range of therapies by navigating the Irish reimbursement process, including HTAs and horizon scans. Now as Head of Consulting at Salutem Insights, she applies this expertise to help clients address complex market access challenges across multiple therapeutic areas.
Dr Roisin Adams, Head of HTA Strategy & External Engagement – NCPE
Roisin led the HTA team for a number of years before being seconded to the HSE to lead a new unit tasked with overseeing and managing high cost drugs in acute hospitals. Roisin is the elected Chair of the Health Technology Assessment Coordination Group which is the governance body responsible for the EU HTA Regulation. She also co- chairs the HTA domain of the BeNeLuxA initiative and is a Director on the Board of the International Horizon Scanning Initiative. She has been awarded a number of grants from the Health Research Board to examine health preferences in Ireland. Her areas of interest include methods for preference elicitation, combining different data for evidence synthesis and reimbursement mechanisms for high cost drugs. Roisin has held advisory positions for Department of Health, the Health Information and Quality Authority and policy direction at EU level.
Orlaith Brennan, Market Development Director – IQVIA
Orlaith has over two decades of experience across the Irish and European healthcare landscape. She brings deep expertise in market access, pricing and reimbursement, and government affairs, having held strategic roles in industry, trade associations, and consultancy. Orlaith played a significant role in negotiating the 2012 and 2016 Framework Agreements between the Irish State and the pharmaceutical industry during her tenure as Director of Commercial Affairs at the Irish Pharmaceutical Healthcare Association (IPHA). She also represented Ireland on key committees at EFPIA in Brussels, contributing to European policy development in pricing, supply chain, and regulatory affairs.
Currently serving as Market Development Director for Ireland at IQVIA, Orlaith leads the design and delivery of innovative market access and healthcare technology solutions for the Irish market. She leverages IQVIA’s global capabilities alongside her nuanced understanding of the Irish healthcare system to help clients navigate complex access environments and drive better patient outcomes. Orlaith is a pharmacist and holds an MBA and advanced diplomas in Health Economics and Public Procurement Law.
Marian Hernon, Health Economics Manager – Amgen
Marian is a Health Economics Manager at Amgen Ireland with over 10 years of experience working in the Irish Health System and reimbursement landscape. Marian plays a pivotal role in navigating complex reimbursement pathways and shaping access strategies for innovative therapies across the Amgen pipeline. Prior to joining Amgen, she held a leadership role at AXIS Healthcare Consulting Ltd., where she served as Associate Director. During her tenure, she led the technical team in developing multiple deliverables across the reimbursement process including rapid reviews, HTAs, modelling, access negotiations and evidence generation studies. Her academic background includes a Bachelor of Arts and a Master’s in Population Health and Health Promotion from the National University of Ireland, Galway, as well as advanced training in decision modelling and economic evaluation from the University of York and University of Birmingham. Her work is grounded in a commitment to the improving quality of life of patients through evidence-based access strategies and collaborative stakeholder engagement.
Kate O’Reilly, Healthcare Transformation Partner – Roche
Kate is a pharmacist with 10+years of experience working across the health and life sciences sectors, including across clinical settings, pharmaceutical regulation, academia, digital health and consulting. As Healthcare Transformation Partner at Roche Products Ireland Limited, Kate is focused on driving patient and system partnership activity, a key component of which involves collaborating with patient communities to amplify the patient voice and integrate the lived perspective across decision making. Alongside her work in patient engagement, Kate holds the position of Vice President on the Board of Directors of the Dublin Healthcare Businesswomen’s Association (HBA) Chapter.
She is also an active member of the global HLTH INCinnovation community and the local Health 2.0 Dublin leadership team. In addition to holding a Master’s degree in Pharmacy, Kate also holds a PhD in Neuropharmacology both from TCD.
She was recently selected by the European Patients’ Academy on Therapeutic Innovation (EUPATI) as one of its ‘HTA Ambassadors’ under the EU HTA4Patientsproject.
Stephanie Stengel, Senior Manager, Market Access – Ecker & Ecker GmbH
Stephanie is a Market Access professional with over 5 years of experience in the healthcare and life sciences sector. She holds a PhD in Molecular Life Science and has been with E+E since 2020, where she currently serves as Expertise Lead for EU HTA and International Market Access.
Her work spans both German Market Access and the evolving EU HTA landscape.
Stephanie has been responsible for and actively contributed to more than 10 AMNOG dossiers across a wide range of therapeutic areas, including oncology, rare diseases, and chronic conditions, covering various settings such as first assessments, extensions of indication, and full assessments of orphan drugs. Her expertise also includes early scientific advice and price negotiations.
In recent years, Stephanie has focused on EU HTA, guiding pharmaceutical companies in navigating the challenges of the Joint Clinical Assessment (JCA). She has supported strategy development, provided internal and external trainings, and is currently leading the preparation of several JCA dossiers.
With her combined expertise in German and European Market Access, Stephanie brings a unique perspective in aligning local and EU-level requirements and supporting clients in developing robust, future-proof access strategies.
Sandra Redmond, Managing Director – Salutem Insights
Sandra is the Managing Director of Salutem Insights and an economist with deep expertise in health economics and market access strategy. With over two decades in the pharmaceutical industry, she has advised on complex reimbursement processes, health technology assessments (HTAs), and policy shaping across a wide range of therapeutic areas. Sandra combines analytical rigour with commercial insight to help clients navigate market access challenges, drawing on her extensive experience to develop evidence-based solutions that drive patient access and sustainable outcomes.
——-
Proudly supported by:
Salutem Insights are a leading health economics and market access consultancy based in Ireland. The firm supports pharmaceutical and biotech companies in navigating the complex Irish reimbursement landscape, drawing on deep expertise in health technology assessments (HTAs), rapid reviews, pricing strategy, and stakeholder engagement. By combining rigorous economic analysis with practical market insight, Salutem Insights helps clients secure patient access for new and existing therapies across a range of therapeutic areas.
Please note that by registering for this event you agree to share your name and company details with the organisers and the event sponsor.
